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Abstract Genistein belongs to isoﬂavones, which are a
subclass of ﬂavonoids, a large group of polyphenolic
compounds widely distributed in plants. Numerous in vitro
studies suggest that isoﬂavones, particularly genistein,
have both chemopreventive and chemotherapeutic poten-
tial in multiple tumor types. However, the molecular and
cellular mechanisms of genistein effects on human ovarian
cancer cells are still little known. In the present study, we
investigated anticancer activity of genistein and its
natural glucoside, genistein-8-C-glucoside isolated from
ﬂowers of Lupinus luteus L. We examined the effects of
the two isoﬂavones alone or in combination on cultured
human SK-OV-3 ovarian carcinoma cells. The cells were
exposed to genistein and genistein-8-C-glucoside at var-
ious concentrations (1–90 µM) for 24 and 48 h. The cyto-
toxic and apoptotic properties of compounds were studied
by the colorimetric 3-[4,5-2-yl]-2-5-diphenyltetrazolium
bromide assay and the acridine orange/ethidium bromide
staining technique. The morphological features of SK-OV-
3 cells were examined by Nomarski differential inter-
ference contrast combined with a confocal laser scanning
microscope. The level of ROS was evaluated with
ﬂuorescence probes: dichloroﬂuorescein-diacetate by ﬂow
cytometry. Changes in mitochondrial membrane potential
were determined using 5,5,6,6-tetrachloro-1,1,3,3-tetra-
ethylbenzimidazolcarbocyanine iodide. Genistein-
treatment and genistein-8-C-glucoside-treatment resulted
in the inhibition of cell proliferation, induction of apoptotic
cell death and loss of mitochondrial membrane potential.
The present data provide the ﬁrst evidence in vitro that
genistein-8-C-glucoside and combination genistein-genis-
tein-8-C-glucoside could be a potential chemotherapeutic
candidate for ovarian cancer therapy.
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Epithelial ovarian cancer is the leading cause of death
among gynecological malignancies in developed nations.
With current protocols, although 70–80 % of patients
respond to front-line chemotherapy, the majority relapses
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and ultimately succumbs to metastatic disease. The suc-
cessful treatment of ovarian cancer depends greatly upon
the effectiveness of cytotoxic anticancer drugs. Chemore-
sistance is related to relapse to ovarian cancer, but the
underlying mechanisms are still poorly understood. There-
fore, identiﬁcation of novel agents against chemoresistant
disease is still a major medical problem (Ahn et al. 2004;
Hajra and Liu 2004; Gossner et al. 2007).
The ﬂavonoids comprise a class of polyphenolic plant
products that possess many biological properties
offering possible new strategies for cancer chemotherapy
(Lamartiniere 2000; Cooke et al. 2006; Klein and King
2007). Genistein (4′,5,7-trihydroxyisoﬂavone), a natural
isoﬂavone phytoestrogen present in soybeans, is a potent
agent in the prophylaxis and treatment of cancer. Like most
isoﬂavones, genistein usually exists in nature in its 7-
glycoside or 8-glycoside form, rather than in its aglycone
form. Whether the isoﬂavones are biologically active in
their glycosidic forms or require hydrolysis to their agly-
cone forms for activity is still a subject of some controversy
(Choi et al. 2007).
Since the discovery by Akiyama et al. (1987) that gen-
istein isolated from the fermentation broth of Pseudomonas
species, inhibited the tyrosine-speciﬁc protein kinases of the
epidermal growth factor (EGF) receptor, several in vitro
studies have documented that genistein can inhibit the
growth of various cancer cell lines: leukemia, lymphoma,
prostate, breast, lung, and head or neck (Yoon et al. 2000;
Sarkar and Li 2002; Klein and King 2007). It is generally
believed that the free genistein aglycone undergoes
absorption and exerts numerous biological activities, of
which anticancer effects are abundantly proved (Polkowski
et al. 2004). These may be mediated through the following
mechanisms of action: induction of apoptosis, protein-
tyrosine kinase induction, G2/M phase cell cycle arrest,
inhibition of DNA topoisomerase II, suppression of telo-
merase activity, and inhibition of angiogenesis (Akiyama
et al. 1987; Markovits et al. 1989; Buchler et al. 2003;
Polkowski et al. 2004; Baxa et al. 2005). These activities,
along with low toxicity, make genistein an important can-
didate for experimental therapy, as well as a new lead-
compound for anticancer drug design. Although genistein’s
molecular mechanisms of action have been studied in
multiple tumor types (cell types), little has been elucidated
with regard to its antineoplastic (anticancer) potential in
ovarian cancer.
Studies have been made on various applications of
genistein showing its high anticancerogenic potential. In
spite of numerous therapeutic properties of genistein there
are still many limitation, concerning its clinical application.
They involve relatively low bioavailability of this com-
pound, which a connection with two-phase action (in
human cancer cell lines, genistein acts as a growth
stimulator at low concentrations, and as a growth inhibitor
at high concentrations) is a main reason why the practical
use of genistein in cancer therapy is limited. Therefore, it is
important to search for new derivatives of genistein
(including other sources than soy) that can possess better
physiochemical characterization or exhibit higher antic-
ancerogenic activity. In this study, we investigated and
compared the possible cytotoxic effects of genistein and its
natural glycosylated derivative, genistein-8-C-glucoside
(G8CG; Fig. 1) from Lupinus luteus L. in human SK-OV-
3 ovarian carcinoma cells. G8CG-induced cytotoxicity in
cancer cell lines has not yet been reported, but accounts of
our previous studies (Rucinska et al. 2007; Rucinska and
Gabryelak 2009) have suggested that G8CG has a biolo-
gical activity. Therefore, we sought to determine whether
these isoﬂavones alone or/and in combination exert a
cytotoxic activity in ovarian cancer cells.
Materials and methods
Cell culture
Ovarian carcinoma cell line (SK-OV-3) was purchased from
Child Health Centre in Warsaw (Poland). Cells were grown
as a monolayer in McCoy’s 5a medium supplemented with
10 % fetal bovine serum with 100 units/ml gentamycin. The
cultures were incubated at 37 °C in an atmosphere of 5 %
CO2 and 95 % air with more than 95 % humidity. For
experiments, exponentially growing cells were used. Cells
growing as a monolayer culture were harvested by trypsi-
nisation (0.25 % trypsin + 0.02 % EDTA). In our pre-
liminary experiments such culture conditions were found to
be optimal for maintaining the best parameters of cell pro-
liferation and viability.
Chemicals
Genistein, phosphate-buffered saline (PBS), dimethyl
sulfoxide (DMSO), dichloroﬂuoroscein-diacetate (H2DCFDA),






Fig. 1 Chemical structure of genistein (a) and G8CG (b)
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3-[4,5-2-yl]-2-5-diphenyltetrazolium bromide (MTT), 5,5,6,6-
tetrachloro-1,1,3,3-tetraethylbenzimidazolcarbocyanine iodide
(JC-1), carbonylcyanide p-chloromethoxyphenylhydrazone
(CCCP), were purchased from Sigma (St. Louis, MO, USA).
McCoy’s 5a medium, RPMI 1640 medium, trypsin, fetal
bovine serum, and gentamycin were obtained from Gibco
(BRL). Tissue culture dishes and ﬂasks were purchased
from Nunc (Roskilde, Denmark). All other reagents and
solvents were of analytical grade.
Chemical treatment of cells
G8CG was isolated from ﬂowers of lupine (Lupinus luteus
L.) according to the method developed by Laman and
Volynets (1974). The isoﬂavon was subsequently extracted
by methanol, ethylacetate, n-butanol and puriﬁed using a
chromatographic column (3 × 80 cm) packed with poly-
amine and the column was washed subsequently with 15,
30, 50, and 80 % ethanol. G8CG was eluted by 50 %
ethanol. G8CG was a beige powder with a purity of 97.5 %
and was stored in a refrigerator (below −4 °C); protected
from light, under nitrogen. Genistein and G8CG were taken
from stock solution (500 μM) in 1 % DMSO. The con-
centration of DMSO used in this study as a vehicle had no
effect on SK-OV-3 cell viability in our preliminary studies.
Genistein or G8CG was added to the suspension of cultured
cells to give a ﬁnal concentration in the range of 1–90 μM.
The cells were incubated with the isoﬂavones alone or in
combination for 24 or 48 h at 37 °C. The control cells were
treated with PBS (pH 7.4). All the ﬂuorophores were dis-
solved in DMSO, and stored at −20 °C. JC-1 (1 μM ﬁnal
concentration) was added directly to the cell culture med-
ium and incubated at 37 °C for the appropriate time,
depending on the ﬂuorophore.
Cell proliferation assay
Proliferation of the cells was measured using the method of
Mossman (1983). The cells were placed in 96-well micro-
titer plates at an initial density of 3 × 104 cells in 200 μl per
well. They were treated with genistein and G8CG (1–90
μM) at 37 °C in a 5 % carbon dioxide—95 % air atmosphere
for 24 and 48 h, and recovered by gentle washing with PBS
(pH 7.4) twice. After incubation, cell proliferation was
determined by the MTT assay. MTT was dissolved in PBS
at 5 mg/ml. Brieﬂy, 50 μl of MTT solution was added to
each well, followed by 4 h of incubation. After the incu-
bation, MTT-containing medium was removed, and 100 μl
of DMSO was added to each well to dissolve formazan
crystals. Absorbance of the converted dye was measured
at 545 nm with a correction at 630 nm using an enzyme-
linked immunosorbent assay plate reader (Awarness
Technology Inc.) Stat Fax Type. Cell viability was
calculated as the percent ratio of absorbance of the samples
to the referent control.
Assessment of apoptosis
The percentage of apoptotic and viable cells was determined
by the AO/EB staining technique described by Duke and
Cohen (1992). An aliquot of 100 μl cell suspension
(1 × 106) previously exposed to genistein and G8CG at ﬁnal
concentrations in the range of 2.5–90 μM was added
to the mixture of AO and EB (AO, 0.13 mM; EB, 0.23 mM)
and incubated for 5 min at 37 °C in the dark. Fluorescent
microscopy (Olympus IX70, Japan) was used to identify
non-viable cells whose nuclei stained bright orange. Viable
cells excluded EB and stained bright green. Quantitative
assessments were made by determining the percentage of
apoptotic cells, whose nuclei are highly condensed or
fragmented. Three hundred images were randomly selected
from each sample. Morphological evaluation of different
stages of apoptosis was also analyzed in Nomarski DIC
microscopy combined with confocal laser scanning
microscope Pascal (Zeiss) equipped with Axiovert 200
upright microscope. Membrane blebs and condensed or
pyknotic nuclei in the cells were regarded as indicators of
apoptosis.
Detection of mitochondrial membrane potential (Δψm)
JC-1 is a lipophilic carbocyanine that exists in a monomeric
form and is able to accumulate into mitochondria. In the
presence of a high mitochondrial membrane potential
(Δψm), JC-1 can reversibly form aggregates which, after
excitation at 488 nm, can be detected in the red channel
(FL2). On the other hand, cells with low Δψm are those in
which JC-1 maintains a monomeric form, showing green
ﬂuorescence (FL1). The ratio of red-green JC-1 ﬂuores-
cence is dependent only on the mitochondrial membrane
potential (Cossarizza et al. 1993). Cells were stained with
the Δψm-sensitive probe JC-1 used at the ﬁnal concentra-
tion of 1 μM in fresh RPMI 1640 medium for 20 min at
room temperature in the dark. The samples were washed
twice by centrifuging at 500 g for 5 min with a double
volume of PBS, and re-suspended in 0.5 ml of PBS, then
immediately analyzed with the ﬂow cytometer. JC-1 was
excited at 488 nm, two different signals were collected on
FACScan at 525 nm (FL1) and the aggregate signal (red)
was analyzed at 590 nm (FL2).
Determination of ROS generation
The level of reactive oxygen species (ROS) was stimulated
with ﬂuorescence probes-H2DCFDA by ﬂow cytometry.
H2DCFDA is a vital ﬂuorescent probe that enters the cell
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and is hydrolyzed to dichloroﬂuorescein (DCF), whose
interaction with peroxides gives rise to 2′,7′-dichloro-
ﬂuorescin (Vanden Hoek et al. 1998). H2DCFDA was
dissolved in DMSO at a concentration of 20 μM and
stored at 4 °C. The cell suspension (1 × 106) was treated
with genistein and genistein-8-C-glycoside (from 2.5 to 90
μM) alone and in combination for 24 h at 37 °C. The
cells were then washed twice in PBS (pH 7.4) and then
gently re-suspended in RPMI 1640 medium and incubated
for 30 min in the presence of 20 μM H2DCFDA. The
ﬂuorescence intensity of DCF was detected using ﬂow
cytometry (Becton Dickinson, LSR). The excitation
and emission wavelengths were set at 488 and 530 nm,
respectively.
Statistical analysis
Data are presented as means±SD from at least ﬁve sets of
measurements. The statistical difference between the con-
trol and treated groups was evaluated by the Student’s t-test.
p< 0.05 and below was accepted as statistically signiﬁcant.
Results
Antiproliferative activity of genistein and G8CG
The effects of genistein and G8CG either alone or in
combination on the proliferation of SK-OV-3 cells were
Fig. 2 Cell proliferation after 24
or 48 h exposure of SK-OV-3
cells to: a genistein; b G8CG;
c genistein-G8CG. The data are
expressed as a percentage of the
control value (value obtained for
untreated cells). Each result
represents mean±SD, n= 4,
*p< 0.05, **p< 0.01,
***p< 0.001
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assessed by the MTT method. Genistein and G8CG
signiﬁcantly decreased cell proliferation after 24 or
48 h of exposure in a dose-dependent and time-dependent
manner (p< 0.05, p< 0.01, p< 0.001, Figs. 2a, b).
Treatment of SK-OV-3 cells with genistein and G8CG
(1–20 µM) for 24 h did not affect cell proliferation,
but the growing concentrations (>20 µM) decreased
cell viability. Treatment with 90 µM G8CG inhibited cell
proliferation by up to 52 % (24 h) and 61.1 % (48 h)
compared to the control. When cells were treated with a
combination of genistein and G8CG at 50 or 90 µM
each, proliferative cell growth was blocked considerably
(p< 0.01, p< 0.001, Fig. 2c). A 66.3 % (48 h) reduction in
cell viability was observed for the 90 µM combination,
which is similar to the decrease observed with 90 µM G8CG
alone (61.1 %). Our results show that the tested compound







































Fig. 3 Induction of apoptosis
after 24 or 48 h exposure of SK-
OV-3 cells to: a genistein;
b G8CG; c genistein-G8CG.
The number of cells in
individual experiments was 300.
Each result represents mean
±SD, n= 4, *p< 0.05, **p<
0.01, ***p< 0.001. Cells were
treated with genistein, G8CG
and genistein-G8CG
combination (50 µM) for 24 h.
The apoptosis was detected by
AO/EB reaction technique,
400X; ﬂuorescent microscopy
and Nomarski DIC, CLSM,
scale bar 20 µM (d)
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Apoptotic effect of genistein and G8CG
The percentage of apoptotic cells detected by the AO/EB
staining technique after treatment with genistein and
G8CG either alone or in combination (2.5–90 µM) for 24
and 48 h was evaluated. Lower, physiological concentra-
tions of genistein and G8CG (2.5–10 µM, 24–48 h) did not
induce apoptotic cell death. The analysis indicated
that the exposure to high concentrations of genistein and
G8CG (50 or 90 µM) signiﬁcantly affected apoptosis in a
dose-dependent and time-dependent manner (p< 0.05, p<
0.01, p< 0.001, Figs. 3a, b). However, the apoptotic effect
of genistein is weaker than that of G8CG at the same
concentrations. Treatment with 90 µM G8CG increased
the number of apoptotic cells by approximately 29 % (24 h)
and 49 % (48 h) compared to untreated cells. A more
pronounced, dose-dependent effect was observed after
48 h exposure to 50 or 90 µM genistein-G8CG combination;
40 and 64 % of apoptotic cells, respectively (p< 0.001,
Fig. 3c). Apoptosis was also visualized by ﬂuorescent
microscopy (AO/EB assay) and confocal laser scanning
microscopy (Contrast of Nomarski). The treatment
of cells with genistein, G8CG, and genistein-G8CG com-
bination (50 µM, 24 h) caused nuclei to become highly
condensed or fragmented. Morphological features
typical of apoptosis: gigantic cells with cytoplasmic
bridges, nuclear condensation or fragmentation, membrane
blebbing, and cytoplasmic granularity were also observed
(Fig. 3d).
Fig. 4 Loss of mitochondrial
membrane potential (ΔΨm) after
24 and 48 h exposure of SK-
OV-3 cells to: a genistein; b
G8CG; c genistein-G8CG. The
calculated ratio of FL2 vs. FL1
of each sample is depicted. The
data are expressed as a
percentage of the control value
(value obtained for untreated
cells). Each result represents
mean±SD, n= 4, *p< 0.05,
**p< 0.01, ***p< 0.001
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Genistein and G8CG induce mitochondrial membrane
depolarization
Changes in mitochondrial membrane potential (ΔΨm) were
determined by staining cells with the mitochondria-speciﬁc
probe, JC-1. Genistein and G8CG signiﬁcantly reduced
ΔΨm after 24 or 48 h of exposure in a dose-dependent and
time-dependent manner (p< 0.05, p< 0.01, p< 0.001,
Figs. 4a, b). Treatment of SK-OV-3 cells with lower, phy-
siological concentrations of genistein and G8CG for 24 and
48 h did not cause changes in the mitochondrial membrane
potential. However, the exposure to high concentrations of
genistein (≥10 µM) and G8CG (≥30 µM) strongly induced
depolarization of ΔΨm. Genistein and G8CG (90 µM)
reduced mitochondrial membrane potential by 52.7 and
49 % (48 h), respectively. A more dramatic drop in the red
ﬂuorescence was observed after 48 h exposure to 50 or
90 µM genistein-G8CG combination; 36.8 and 56.8 %,
respectively (p< 0.01, p< 0.001, Fig. 4c). These ﬁndings
suggest that mitochondria could be a primary target for
genistein-induced and G8CG-induced apoptosis and that
loss of ΔΨm is an early event in the process.
ROS generated by genistein and G8CG
Generation of ROS was veriﬁed by the measurement of
changes in ﬂuorescent intensity of H2DCFDA resulting
from intracellular probe oxidation. Fluorescence intensity
can be easily measured and it is the basis of the popular
cellular assay for oxidative stress. The effects of genistein
and G8CG either alone or in combination on H2DCFDA
ﬂuorescence is shown in Figs. 5a–c, respectively (p< 0.05,
p< 0.01, p< 0.001). The results show that high con-
centrations of genistein or G8CG (≥20 µM) and genistein-
G8CG combination (≥10 µM) increased DCF ﬂuorescence,
which suggests that these isoﬂavones can cause DCF oxi-
dation by generating reactive species, in particular H2O2. In
contrast, after the treatment with lower concentrations of the
compounds (2.5–20 µM), the rate of ROS generation was
not different from the rate observed in normal cells. The
Fig. 5 ROS production after 24
and 48 h exposure of SK-OV-3
cells to: a genistein; b G8CG; c
genistein-G8CG. ROS
production was measured as
DCF ﬂuorescence. Each result
represents mean±SD, n= 4,
*p< 0.05, **p< 0.01,
***p< 0.001
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obtained results show that the treatment of SK-OV-3 cells
with genistein and G8CG generates ROS, including H2O2,
suggesting that these ﬂavonoids can induce ROS-dependent
apoptosis.
Discussion
Epithelial ovarian cancer is a very common malignancy in
industrialized nations and is highly chemoresistant to cur-
rently available chemotherapeutic agents. In a large
screening, in vitro studies have documented that numerous
isoﬂavonoids could prevail over the resistant capacity and
display effective antiproliferative activities in various can-
cer cell lines. Dietary relevant sources of isoﬂavonoids,
represented by genistein, are soybeans and soy derived
foodstuffs. The interest in genistein originated from epide-
miological ﬁndings indicating that it may provide protection
against chronic diseases such as hormone-dependent can-
cers (Lee et al. 1991; Adlercreutz et al. 1993) and disorders
of cardiovascular system (Setchell and Cassidy 1999).
Subsequent studies revealed that genistein exhibits
multiple pharmacological effects, so at present the iso-
ﬂavone is emerging as an active ingredient for nutraceu-
ticals or as a prospective drug candidate for anticancer
therapy (Polkowski and Mazurek 2000; Dixon and Ferreira
2002; Popiołkiewicz et al. 2005). The estrogenic activity of
genistein and its subsequent modulation of cellular pro-
cesses in tumorigenic ovarian cells are not well
characterized.
In the present study, we were the ﬁrst to investigate
anticancer activity of free aglycone genistein and its natural
glucoside, G8CG isolated from ﬂowers of Lupinus luteus L.
in cultured human SK-OV-3 ovarian carcinoma cells. We
examined the effect of the two isoﬂavones alone or in
combination in various concentrations (2.5–90 µM, 24 or
48 h) on cell proliferation, induction of apoptotic cell death,
mitochondrial membrane potential and the level of ROS in
cells. It has been reported that low-dose concentrations of
genistein, comparable to physiological levels achieved
with dietary intake of isoﬂavones including genistein,
produce a stimulatory effect on estrogen-dependent human
breast cancer cells in vitro and in vivo (Allred 2001; Ju
2001). To determine whether this effect was also seen in
ovarian cancer cells, SK-OV-3 cells were treated with
physiological concentrations of genistein and G8CG (1–10
µM) for 24–48 h. In our studies, low-dose genistein and
G8CG treatment did not result in proliferation of ovarian
cancer cells when compared to the control. We demon-
strated that high doses of genistein signiﬁcantly decreased
cell proliferation, which was consistent with previously
published reports indicating that genistein may be an
effective agent against cancer. Genistein has been
reported to inhibit the proliferation of several cancer cell
lines. Our observations are in agreement with in vitro results
in several ovarian tumor cells: A2780, CaOV3, ES2, and
SK-OV-3 (Choi et al. 2007; Gossner et al. 2007), which
indicated that high, supraphysiological concentrations (>10
µM) of genistein exhibit a cytotoxic activity. Like genistein,
G8CG and a combination of genistein-G8CG at high con-
centrations inhibited proliferation of SK-OV-3 cells, sug-
gesting that G8CG possesses an antiproliferative effect
similar to that of non-glycosylated genistein. Recently, our
research provided direct evidence that G8CG from Lupinus
luteus L. is able to inhibit proliferation of hamster ovary
CHO cells and mouse NIH 3T3 cells in vitro (Rucinska
et al. 2007, 2008).
Inhibition of cell proliferation has been associated with
induction of apoptosis in other cell types (Allred 2001). In
epithelial cells, apoptosis is an early response to cell death.
Although genistein has been shown to induce apoptosis in a
variety of human cancer cells, its mechanism of action is not
fully known. Some recent works provide evidence that
genistein can induce not only apoptosis, but also autophagic
cell death, in overlapping or parallel scenarios. Gossner
et al. (2007) observed that the mechanism of genistein-
induced cell death involves both apoptosis and autophagy.
Because autophagy is typically an adaptive response to
nutrient starvation, scientists hypothesized that genistein
could induce a starvation-like signaling response. We have
now demonstrated that the treatment of SK-OV-3 cells with
genistein and G8CG (50 or 90 µM, 24 or 48 h) induced
apoptotic cell death in a dose-dependent and time-
dependent manner, which was consistent with the litera-
ture. We also postulate that genistein and G8CG combined
are more effective than genistein alone. It is possible that
apoptosis induction by G8CG may have a different pathway
than genistein. This apoptotic effect may be explained by
difﬁcult concentrations; i.e., high doses of isoﬂavones may
produce a deleterious effect (Leopold et al. 1976; Setchell
et al. 1987) and induce apoptosis through mitochondrial-
dependent pathways. Yoon et al. (2000) demonstrated that
genistein (90 µM, 24 h) induced cytochrome c release,
caspase-3 activation, nuclear condensation and DNA frag-
mentation by reducing the mitochondrial membrane
potential. Lower, but not quite physiological concentrations
of genistein (15–60 µM) induced apoptosis in murine T-cell
lymphoma cell lines via mitochondrial depolarization
(Baxa et al. 2005). In recent years, numerous studies have
demonstrated that most, if not all, cells experience a col-
lapse of their mitochondrial membranes as a prelude to
nuclear DNA degradation and apoptosis (Ravagnan et al.
2002). Indeed, mitochondria are now thought to act as key
coordinators of apoptosis (Green and Reed 1998).
In agreement with this, we have shown here that, in SK-
OV-3 cells, genistein and G8CG alone or in combination
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induce depolarization of the mitochondrial membrane
potential. Lower concentrations of isoﬂavones (<10 µM)
did not induce mitochondrial depolarization. It is ques-
tionable, whether genistein would have any effect on
mitochondrial-dependent apoptosis at physiologically rele-
vant levels (Klein and King 2007). Our data let us suggest
that mitochondria could be one of the targets for the action
of genistein and its derivative.
Increasing evidence suggests that ROS can also induce
apoptotic cell death and can act as a target for anticancer
strategy. In this study, the data showed that genistein and
G8CG (≥20 µM, 24 and 48 h) induced a signiﬁcant increase
in ROS production and loss of ΔΨm. Because ROS are well
recognized to act as secondary messengers in diverse
intracellular signaling cascades, they may be the main
molecules responsible for the observed cytotoxic effects
(Yeh et al. 2007). Cao et al. (1997) proposed a reaction
sequence for ROS production by ﬂavonoids, whose ﬁrst
step requires the oxidized state of involved transition metal,
which is decreased by reacting with the ﬂavonoids in a
reduced form. Mitochondrial DNA is particularly suscep-
tible to damage by ROS because of its close proximity to
the electron transport chain and its lack of protective his-
tones. Prolonged dissipation of ΔΨm might be attributed to
this susceptibility to mitochondrial DNA damage. Taken
together, the data suggest that an interaction with mito-
chondria might partially explain the apoptotic cell death
during a long-term exposure to genistein or G8CG.
In summary, our studies demonstrated that genistein and/
or G8CG exerted multiple suppressive effects on SK-OV-3
cells, including proliferation inhibition, induction of apop-
tosis, collapse of mitochondrial membrane potential, and
generation of ROS. Most importantly, our data provide the
ﬁrst evidence that G8CG and genistein-G8CG combination
could be potential candidates for ovarian cancer therapy.
These ﬁndings provided a basis for further investigation on
genistein and G8CG for the treatment and prevention of
ovarian cancer.
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